Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues

Autor: Broquetas, Teresa, Garcia-Retortillo, Montserrat, Hernandez, Juan José, Puigvehí, Marc, Cañete Hidalgo, Nuria, Coll, Susanna, Cabrero, Beatriz, Giménez, Maria Dolors, Solà, Ricard, Carrión, José A., Universitat Autònoma de Barcelona
Rok vydání: 2017
Předmět:
0301 basic medicine
Male
HBsAg
Chronic Hepatitis
Biopsy
lcsh:Medicine
medicine.disease_cause
Gastroenterology
Biochemistry
Chronic Liver Disease
Hepatitis
0302 clinical medicine
Medicine and Health Sciences
Public and Occupational Health
Hepatitis B e Antigens
lcsh:Science
Pathology and laboratory medicine
Multidisciplinary
Liver Diseases
virus diseases
Hepatitis B
Medical microbiology
Middle Aged
Predictive value
Vaccination and Immunization
Infectious hepatitis
Hbeag negative
Viruses
Infectious diseases
030211 gastroenterology & hepatology
Female
Pathogens
Research Article
Adult
medicine.medical_specialty
Hepatitis B virus
Adolescent
Immunology
Surgical and Invasive Medical Procedures
Gastroenterology and Hepatology
Viral diseases
Hbsag seroclearance
Microbiology
Antiviral Agents
03 medical and health sciences
Young Adult
Hepatitis B
Chronic
Chronic hepatitis
Antiviral Therapy
Diagnostic Medicine
Internal medicine
medicine
Humans
Aged
Retrospective Studies
Hepatitis B Surface Antigens
business.industry
lcsh:R
Viral pathogens
Organisms
Biology and Life Sciences
Proteins
Serum samples
medicine.disease
Fibrosis
Hepatitis viruses
digestive system diseases
Microbial pathogens
030104 developmental biology
lcsh:Q
Preventive Medicine
Interferons
Hepatitis B -- Tractament
business
Developmental Biology
Zdroj: Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
PLoS ONE, Vol 12, Iss 11, p e0188303 (2017)
PLoS ONE
Popis: Background: HBeAg-negative chronic hepatitis B patients require long-term nucleos(t)ide analogues (NAs) because loss of surface antigen (HBsAg) is unusual. Low quantitative HBsAg (qHBsAg) levels can identify patients with higher probability of seroclearance. The aim of our study was to evaluate qHBsAg in HBeAg-negative patients receiving NAs to predict a reduction of HBsAg levels and seroclearance. Methods: Retrospective analysis of qHBsAg in HBeAg-negative patients before and at years 1, 3, 5, 8 and over of NAs treatment. Results: From 1999 to 2015, HBsAg was quantified in 358 serum samples from 95 HBeAg-negative patients. Low qHBsAg (0.3 log IU/mL showing a positive and negative predictive value of 42% and 100% to identify patients achieving low levels of HBsAg. Conclusions: Reduction of qHBsAg is slow in HBeAg-negative patients receiving NAs, although low levels or faster qHBsAg decline may occur in 14%. A qHBsAg reduction >0.3 log IU/mL at year 3 can identify patients with a higher probability of achieving low levels and HBsAg seroclearance.
Databáze: OpenAIRE
Externí odkaz: